We screened variants on an exome-focused genotyping array in >300,000 participants (replication in >280,000 participants) and identified 444 independent variants in 250 loci significantly associated with total cholesterol (TC), high-density-lipoprotein cholesterol (HDL-C), low-densitylipoprotein cholesterol (LDL-C), and/or triglycerides (TG). At two loci (JAK2 and A1CF), experimental analysis in mice showed lipid changes consistent with the human data. We also found that: (i) beta-thalassemia trait carriers displayed lower TC and were protected from coronary artery disease (CAD); (ii) excluding the CETP locus, there was not a predictable relationship between plasma HDL-C and risk for age-related macular degeneration; (iii) only some mechanisms of lowering LDL-C appeared to increase risk for type 2 diabetes (T2D); and (iv) TG-lowering alleles involved in hepatic production of TGrich lipoproteins (TM6SF2 and PNPLA3) tracked with higher liver fat, higher risk for T2D, and lower risk for CAD, whereas TG-lowering alleles involved in peripheral lipolysis (LPL and ANGPTL4) had no effect on liver fat but decreased risks for both T2D and CAD.
Plasma lipid levels are modifiable risk factors for atherosclerotic cardiovascular disease. Genome-wide association studies (GWAS) testing common DNA-sequence variation have uncovered 175 genetic loci affecting lipid levels in the population [1] [2] [3] [4] [5] [6] [7] . These findings have provided information on lipoprotein biology and elucidated the causal roles of lipid levels in cardiovascular disease [8] [9] [10] [11] . Here, we built on these previous efforts to: (i) perform an exome-wide association screen for plasma lipids in >300,000 individuals; (ii) experimentally evaluate discovered alleles; and (iii) test the inter-relationship of mapped lipid variants with CAD, age-related macular degeneration (AMD), fatty liver, and T2D.
We tested the association of genotypes from the HumanExome BeadChip (exome array) with lipid levels in 73 studies including >300,000 participants (Supplementary Note and Supplementary Tables 1-3) across several ancestries, with maximal sample sizes of 237,050 for participants of European ancestry, 16 ,935 for participants of African ancestry, 37,613 for participants of South Asian ancestry, and 5,082 for participants of Hispanic or other ancestry. A companion manuscript describes results for 47,532 East Asian participants 12 . A total of 242,289 variants were analyzed after quality control, approximately one-third of which were nonsynonymous, with minor allele frequency (MAF) <0.1% (Supplementary Table 4 ).
Single-variant association statistics and linkage-disequilibrium information summarized across 1-Mb sliding windows were generated from each cohort in RAREMETALWORKER or RVTESTS 13, 14 software. Meta-analyses of single-variant and gene-level association tests were performed with rareMETALS (version 6.0). Genomic control values for meta-analysis results were between 1.09 and 1.14 for all four traits ( Supplementary Fig. 1 ), suggesting that the population structure in our analysis was well controlled 3, 15 .
We identified 1,445 single variants associated at P < 2.1 × 10 −7 (twotailed score test with Bonferroni correction of 242,289 variants analyzed) (Supplementary Figs. 2-5 ). Full association results are available ('Data availability' section). Of those variants, 75 were 'novel' variants (located at least 1 Mb from previously reported GWAS signals): 35 were protein-altering variants, and 40 were noncoding variants ( Table 1 and  Supplementary Tables 5-7 ). The MAF of the lead variant was >5% at 61 of these 75 loci. Participants of European ancestry provided the most significant associations for the 75 novel loci, with the exception of two LDL-associated variants (rs201148465 and rs147032017), which were driven by the South Asian participants (Supplementary Table 8 ). Gene-level association analyses identified an additional five genes whose signal was driven by multiple rare variants (P < 4.2 × 10 −7 , twotailed score test with Bonferroni-correction threshold for performing five tests on ~20,000 genes, Supplementary Table 9) .
We sought replication in up to 286,268 independent participants from three studies: the Nord-Trøndelag Health Study 16 (HUNT; maximum n = 62,168), the Michigan Genomics Initiative (MGI; maximum n = 6,411; URLs) and the Million Veteran Program (MVP; maximum n = 218,117). Of the novel primary trait associations, 73/73 associations were directionally consistent (Supplementary Table 10 ); two SNPs were not available for replication (rs201148465 and rs75862065). Furthermore, we were able to replicate the associations of 66/73 (90%) at α = 0.05.
At any given genetic locus, multiple variants may independently contribute to plasma lipid levels. We quantified this phenomenon by iteratively performing association analyses conditional on the top variants at each locus. We identified 444 variants independently associated with one or more of the four lipid traits in 75 novel and 175 previously implicated loci ( Supplementary Fig. 6 and Supplementary  Tables 11 and 12) .
The identification of lipid-associated coding variants may help to refine association signals at previously identified GWAS loci. We were able to evaluate this possibility in 131 of the 175 previously reported GWAS loci where the index or proxy variant was available on the exome array and associated with lipid levels with P < 2.1 × 10 −7 (twotailed score test; Supplementary Tables 13 and 14) . For example, an intronic SNP (rs11136341, close to the PLEC gene) associated with LDL-C was the original lead SNP in its GWAS locus (P = 2 × 10 −13 ). In the current study, a protein-altering variant in PARP10 was the top variant in the same locus (rs11136343; p.Leu395Pro; P = 7 × 10 −26 ). After conditioning on PARP10 p.Leu395Pro, the evidence for rs11136341 diminished (P = 0.02); in contrast, PARP10 p.Leu395Pro remained significant (P = 9 × 10 −13 ) after conditioning on rs11136341. PARP10 has been shown to affect the hepatic secretion of apolipoprotein B (apoB) in human hepatocytes 17 ; these results prioritize PARP10 as a causal gene at this locus.
Experimental analysis of discovered mutations in model systems is a powerful approach to validate the results of human genetic analyses. We prioritized two coding alterations for experimental analysis: Janus kinase 2 (JAK2) p.Val617Phe and APOBEC1 complementation factor (A1CF) p.Gly398Ser. JAK2 p.Val617Phe is a recurrent somatic alteration that arises in hematopoietic stem cells and can lead to myeloproliferative disorders or clonal hematopoiesis of indeterminate potential [18] [19] [20] [21] [22] . We Fig. 7 ). This result was consistent with our human genetic observations. The mechanism by which the JAK2 p.Val617Phe alteration leads to lower plasma TC and LDL-C but higher risk for CAD requires further study.
Another new association that emerged from the genetic analyses was between A1CF p.Gly398Ser and TG (MAF 0.7%, 0.10-s.d. increase in TG per copy of alternative allele, P = 4 × 10 −11 , two-tailed score test); this variant was also associated with higher circulating TC (P = 4 × 10 −7 , two-tailed score test) and was nominally associated with a higher risk of CAD (odds ratio (OR), 1.12; P = 0.02, two-tailed logistic regression). A1CF encodes APOBEC1 complementation factor, an RNA-binding protein that facilitates the RNA-editing action of APOBEC1 on the APOB transcript 25,26 . We performed CRISPR-Cas9 deletion, rescue, and knock-in experiments to assess whether A1CF p.Gly398Ser is a causal alteration that alters TG metabolism.
CRISPR-Cas9-induced deletion of A1CF led to 72% and 65% less secreted APOB100 than that in control Huh7 and HepG2 human hepatoma cells, respectively (Fig. 1a-c and Supplementary Fig. 8 ). These findings were consistent with those from previous studies in rat primary hepatocytes, in which significantly decreased apoB secretion has been observed after RNA-interference-based depletion of A1CF 27 . Additionally, cellular APOB100 levels were significantly lower in A1CF-deficient cells (Supplementary Fig. 8b,c) . A subsequent 'rescue' experiment involving overexpression of wild-type or A1CF p.Gly398Ser in Huh7 cells with or without endogenous A1CF expression confirmed higher APOB100 secretion in cell lines expressing A1CF p.Gly398Ser (Fig. 1d) .
We sought to further validate the A1CF gene and the p.Gly398Ser variant by using CRISPR-Cas9 to generate knock-in mice. Using a guide RNA targeting A1cf exon 9, the site of the codon encoding p.Gly398, and a 162-nt single-stranded DNA oligonucleotide-repair template containing the p.Gly398Ser variant as well as additional synonymous changes to prevent recleavage by CRISPR-Cas9, we generated mice on the C57BL/6J inbred background with an allele encoding A1cf p.Gly398Ser (hereafter referred to as KI) ( Supplementary  Fig. 9a,b) . We bred mice to achieve KI-allele homozygosity and found that KI/KI mice were viable and healthy. We compared wild-type and KI/KI colony mates (n = 9 and 8, respectively) with respect to TG levels ( Supplementary Fig. 9c,d ). We found that KI/KI mice had 46% higher TG than did the wild-type mice (P = 0.05). In sum, these results indicated that A1CF is a causal gene for TG in humans and that the p.Gly398Ser variant is a causal alteration with possible relevance to CAD.
Next, we used the 444 identified DNA sequence variants to address four clinical questions. First, a rare null mutation in HBB, encoding beta-globin c.92+1G>A, rs33971440, associated with lower TC (Supplementary Table 15 ) and exhibited the strongest TC-lowering effect after null mutations in PCSK9; this result prompted us to question the relationship between beta-thalassemia and risk for CAD. Approximately 80 to 90 million individuals worldwide have been estimated to carry a heterozygous loss-of-function HBB mutation, termed the beta-thalassemia trait 28 . Observational epidemiologic studies have shown that the beta-thalassemia trait is associated with lower blood cholesterol levels 29, 30 . We found that HBB c.92+1G>A was associated with a 17 mg/dl decrease in LDL-C (95% confidence interval (CI), [−23, −11]; P = 2.7 × 10 −8 two-tailed score test) and a 21 mg/dl decrease in TC (95% CI, [−27, −14]; P = 8.9 × 10 −11 ) (Supplementary Fig. 10 ). In an analysis of 31,156 CAD cases and 65,787 controls, carriers of lossof-function variants in HBB were protected against CAD (OR for CAD, 0.70; 95% CI, [0.54, 0.90]; P = 0.005, two-tailed logistic regression) ( Supplementary Fig. 11 ). We display results for all null mutations with association P <0.001, two-sided test for correlation for any of the four lipid traits (Supplementary Table 15) .
Second, DNA sequence variants in the CETP gene that are associated with higher HDL-C also correlate with higher risk for AMD, a leading cause of blindness [31] [32] [33] [34] [35] ; here, we asked whether any way of increasing plasma HDL-C might predictably lead to increased AMD risk. Across 168 independent HDL-C variants with MAF >1%, we tested the association of each HDL-C variant with AMD risk. The effect size of a variant on HDL-C was positively correlated with its effect on AMD risk (correlation in effect sizes, r = 0.41, P = 4.4 × 10 −8 ; Supplementary  Table 16 and Supplementary Fig. 12 ). However, this effect was driven by the ten independent HDL-C-associated variants in CETP (heterogeneity across the different HDL-C-raising mechanisms (between-study variance (τ 2 ) = 0.91, P value for heterogeneity (P het ) = 1.8 × 10 −15 , two-tailed test of heterogeneity statistic Q)) (Supplementary Table 17 ). When these ten CETP variants were removed, there was no longer a relationship between genetically altered HDL-C and AMD risk (P = 0.17 two-sided correlation of effect sizes). These results suggested that outside of the CETP locus, there is not a predictable relationship between plasma HDL-C and risk for AMD.
Third, we asked whether lowering LDL-C with lipid-modifying medicines would always increase risk for T2D. This question was motivated by the observations that, in randomized controlled trials, statin therapy has been found to increase risk for T2D and that, in l e t t e r s recent reports, PCSK9 variants have been associated with higher risk for T2D [36] [37] [38] . We confirmed the association of PCSK9 p.Arg46Leu with T2D risk among 222,877 participants (Supplementary Fig. 13 ). In addition, across 113 independent LDL-C variants at 90 distinct loci, we compared each variant's effect on LDL-C with its subsequent effect on risk for T2D. Across the 113 variants, there was a weak inverse correlation between a variant's effects on LDL-C and T2D (r = −0.21, P = 0.025); however, there was evidence for heterogeneity in this relationship (τ 2 = 0.50, P het = 2.5 × 10 −9 , two-tailed test of heterogeneity statistic Q). Five LDL-C-lowering genetic mechanisms had the most compelling evidence for association with higher risk for T2D (TM6SF2 p.Glu167Lys, APOE rs769449, HNF4A p.Thr136Ile, PNPLA3 p.Ile148Met, and GCKR p.Leu446Pro) (P < 4.0 × 10 −4 , two-sided score test for each, Bonferroni-correction threshold for performing tests at 113 variants, Supplementary Table  19 and Supplementary Fig. 14) . These results suggested that only some ways of lowering LDL-C are likely to increase risk for T2D. Finally, two key processes-hepatic production and peripheral lipolysis-contribute to blood TG levels. We asked how genes involved in hepatic production of TG-rich lipoproteins (PNPLA3 and TM6SF2) differed from lipolysis-pathway genes (LPL and ANGPTL4) in their effects on the related metabolic traits of blood lipids, fatty liver, T2D, and CAD ( Table 2 ). The alternative alleles at PNPLA3 p.Ile148Met, TM6SF2 p.Glu167Lys, LPL p.Ser474Ter, and ANGTPL4 p.Glu40Lys were all associated with lower blood TG and less risk for CAD. However, the blood-TG-lowering alleles at PNPLA3 and TM6SF2 led to more fatty liver and higher risk for T2D. In contrast, the blood-TG-lowering alleles at LPL and ANGPTL4 were neutral with respect to fatty liver and led to lower risk for T2D. We confirmed the LPL observation by using a phenome-wide association study in the UK Biobank (Supplementary Table 20) . In UK Biobank, a 1-s.d. decrease in TG mediated by LPL variants decreased risks for both T2D and CAD (Fig. 2) .
In summary, by combining large-scale human genetic analysis with experimental evidence, we demonstrated the association of 444 independent coding and noncoding variants at 250 loci with plasma lipids and the use of mouse models and genome editing to pinpoint causal genes and protein-altering variants. We further provided evidence that LPL activation can be expected to lower TG and reduce risks for both CAD and T2D without increasing liver fat and thus may be advantageous for patients with metabolic risk factors.
URLs. Michigan Genomics Initiative, http://www.michigangenomics. org/.
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Study samples and phenotypes. Seventy-three studies contributed association results for exome chip genotypes and plasma lipid levels. The outcomes were fasting lipid values in mg/dl (TC, HDL-C, LDL-C, and TG) from the baseline, or an earlier exam with fasting measures. If a study had only nonfasting levels, then it contributed to only the TC and HDL-C analyses. LDL-C and TG analyses were performed on only fasting lipid values. Lipid-lowering therapy with statins was not routinely used before the publication of the 4S study in 1994, which demonstrated the clinical benefits of statin therapy. Therefore, for data collected before 1994, no lipid-lowering-medication adjustment was applied. For data collected after 1994, we adjusted the TC values for individuals taking lipid-lowering medication by replacing their TC values by TC/0.8; this adjustment estimates the effect of statins on TC values. No adjustment was made on HDL-C or TG. LDL-C was calculated with the Friedewald equation for subjects with TG <400 mg/dl (LDL-C = TC -HDL-C -(TG/5)). If TC was modified as described above for medication use after 1994, then modified TC was used in this formula. If only measured LDL-C was available in a study, we used LDL/0.7 for subjects on lipid-lowering medication when data were collected after 1994. TG values were natural-log transformed. For each phenotype, residuals were obtained after accounting for age, age squared, sex, and principal components (as needed by each study, up to four), and inversenormal-transform residuals were created for analysis.
Genotyping and quality control. All studies used Illumina or Affymetrix Human Exome array v1 or v1.1. Genotypes were determined from Zcall 41 or joint calling 42 . Individual studies used the following quality controls: call rate, heterozygosity, sex discordance, GWAS discordance (if GWAS data were available), fingerprint concordance (if available), and PCA outliers.
Association analyses. For each contributing cohort, ancestries were analyzed within the cohorts separately, and studies collected on case-control status analyzed cases separately from controls. We performed both single-variant and gene-level association tests. In the association analysis, we obtained residuals after controlling for sex, age, age squared, and up to four principal components as covariates. Studies that had related samples analyzed the association by using linear mixed models with relatedness estimated from genome-wide SNPs or from pedigrees. From each study, we collected single-variant score statistics and their covariance matrix for variants in sliding windows across the genome. Summary association test statistics were generated with RAREMETALWORKER or RVTESTS. Using summary association statistics collected from each study, we performed meta-analysis of single-variant association tests by using the Mantel-Haenszel test and constructed burden, SKAT, and variable threshold tests with the approach by Liu et al. 14 . For burden and SKAT, we used MAF thresholds of 1% and 5%, and for VT, we applied a MAF threshold of 5%. In the SKAT test, variants are weighted according to their MAFs, using the beta kernel β (1, 25) .
Using covariance matrices between single-variant association statistics, we were also able to perform conditional association analyses centrally, thereby distinguishing genuine signals from 'shadows' of known loci. Details of the methods can be found in Liu et al. 14 .
We centrally performed quality control for the data. We aligned studyreported reference and alternative alleles with alleles reported in the NHLBI Exome Sequencing Project 43 and removed mislabeled variant sites that could be strand ambiguous. For variant sites in each study, we removed variants that had calls rated <0.9 or had Hardy-Weinberg P values <1 × 10 −7 . Finally, in additional checks, for each study we visually inspected the scatter plot of variantallele frequency against frequencies from ancestry-matched populations in the 1000 Genomes Project 44 , and we made sure that the strand and allele labels were well calibrated among studies.
Single-variant associations with P < 2.1 × 10 −7 (0.05/242,289 variants analyzed) and gene-based associations with P < 4.2 × 10 −7 (0.05/[20,000 genes × 6 tests]) were considered significant. Novel loci were defined as being not within 1 Mb of a known lipid GWAS SNP. Additionally, linkage-disequilibrium information was used to determine independent SNPs in which a locus extended beyond 1 Mb. All novel loci reported in this manuscript were >1 Mb from any previously reported locus and independent (r 2 <0.2 was required for variants within 3 Mb).
Sequential forward selection. To identify independently associated variants for each known and newly identified locus, we performed sequential forward selection. We initialized the set of independently associated variants (denoted Φ), starting with the top association signal in the locus. For each iteration, conditioning on variants in Φ, we performed conditional association analyses for all remaining variants. If the top association signal after the conditional analysis remained significant, we added the top variant to the set Φ, then repeated the conditional association analysis. If the top variant after the conditional analysis was no longer significant, we stopped and reported variants in the set Φ as the final set of independent variants for that locus. We used the same single-variant significance threshold (P < 2.1 × 10 −7 ) to determine statistical significance with the sequential forward-selection results (Supplementary Fig. 6 ).
Annotation. Sequence variants were annotated according to refSeq version 1.9, with SEQMINER software (version 5.7) 45 . Transcript-level annotations were obtained and prioritized. When multiple transcript-level annotations were available, they were prioritized according to their functionality and deleteriousness. To implement gene-level association tests, the annotation with the highest priority was used (along with other filtering criteria such as MAFs) to determine the set of variants that were included. Refinement of genome-wide association signals. We sought to quantify what proportion of GWAS loci might be due to a protein-altering variant and therefore to directly identify a functional gene. We assumed that a protein-altering variant was the most likely causal variant for each region if it was the top signal, explained the signal, or was independent of the original signal. To identify putative functional coding variants accounting for the effects at known lipid loci, we performed reciprocal conditional analyses to control for the effects of known lipid GWAS or coding variants within 500 kb, because this was the maximum distance for variants within the covariance matrix. Loci where coding variants were the most significant signals were considered as 'coding as top' . Loci where the initial GWAS variants had conditional P >0.01 were considered to be explained by the coding variants. Loci where the coding variants had conditional P < 2.1 × 10 −7 were considered to be independent of the initial GWAS signals. Table 21 ) targeting exon 4 of A1CF were constructed by using the lentiviral vector lentiGuide-Puro. Packaged viruses were used to transduce the Cas9-expressing cells for 16 h. Subsequently, cells were cultured in the presence of 5 µg/ml puromycin for 5 d before splitting for assays. Cells for the APOB secretion assay were cultured for 18 h in serum-free medium, then the amount of APOB100 in the medium was measured with an ELISA kit (MABTECH) according to the manufacturer's instructions.
In a rescue experiment, to avoid cutting of the A1CF coding region on the recombinant plasmids by previously designed exon-targeting CRISPRs, four new CRISPRs targeting introns flanking exon 4 were applied to deplete endogenous A1CF. The sequences for those sgRNAs are available in Supplementary  Table 21 . The A1CF p.Gly398Ser variant was generated by using overlapping PCR and was confirmed by Sanger sequencing. Constructs encoding both the wild type and the A1CF p.Gly398Ser variant were incorporated into lentiviral plasmids, respectively. After transduction, cells were cultured for 48 h in the presence of 100 ng/ml doxycycline to induce recombinant expression of A1CF or the p.Gly398Ser variant before different assays were performed.
A1cf p.Gly390Ser knock-in mice. All procedures used for animal studies were approved by Harvard University's Faculty of Arts and Sciences Institutional Animal Care and Use Committee and were consistent with local, state, and federal regulations, as applicable. Knock-in mice were generated with a guide RNA designed to target the orthologous site of the A1CF p.Gly390Ser variant. In vitro-transcribed cas9 mRNA (100 ng/µL; TriLink BioTechnologies) and guide RNA (50 ng/µL) were co-injected with 100 ng/µL single-stranded DNA oligonucleotide (Integrated DNA Technologies) ( Supplementary Table 21 ) into the cytoplasm in fertilized oocytes from C57BL/6J mice. Genomic-DNA samples from founder mice were screened for knock-in mutations by PCR, and the results were confirmed by Sanger sequencing. Positive mice were bred with C57BL/6J mice to generate wild-type and homozygous knock-in mice. Male colony mates at 12 weeks of age were used for lipid measurements. Blood samples were collected from the lateral tail veins after an overnight fast. Plasma triglyceride levels were measured with Infinity Triglycerides Reagent (Thermo Fisher) according to the manufacturer's instructions.
Intersection of lipid-association signals with AMD, CAD, and T2D. To estimate the association of loss-of-function variants in HBB with cholesterol levels, participants from the following two consortia were studied: the Global Lipids Genetics Consortium and the Myocardial Infarction Genetics Consortium (MIGen, 27,939 participants in 12 cohorts). A rare loss-of-function variant in HBB (c.92+1G>A, rs33971440) was genotyped in participants from the Global Lipids Genetics Consortium Exome Consortium. This variant was pooled with sequence data for the HBB gene in MIGen, available for 19,434 participants with blood cholesterol measurements. The association of loss-of-function variants with cholesterol was estimated with linear regression with adjustment for age, sex, and up to five principal components of ancestry. Estimates from genotype and sequence data were pooled by using inverse-variance-weighted fixed-effects meta-analysis.
To estimate the association of loss-of-function variants in HBB with CAD, participants from the following two consortia were studied: the CARDIoGRAM Exome Consortium (69,087 participants from 20 studies) and MIGen (12,384 CAD cases and 15,547 controls from 12 studies). 69,086 individuals who were genotyped for the c.92+1G>A variant in the CARDIoGRAM Exome data were pooled with sequence data for HBB from 27,931 individuals in MIGen. The association of loss-of-function variants with CAD was estimated through logistic regression with adjustment for age, sex, and up to five principal components of ancestry. Estimates were pooled with inverse-variance-weighted fixed-effects meta-analysis. To estimate the association of loss-of-function variants in HBB with hemoglobin and hematocrit levels, estimates from an exome chip analysis of red-blood-cell traits (24,814 individuals) were used.
For 168 variants independently and significantly associated with HDL-C and a MAF >1%, we looked up the association evidence in 16,144 AMD cases and 17,832 controls with exome chip genotypes 46 .
For 132 independently and significantly associated LDL-C variants and MAF >1%, we looked up the association evidence in (i) up to 120,575 individuals with or without CAD and exome chip genotypes (42,335 cases and 78,240 controls) 40 and (ii) up to 69,870 individuals with or without T2D. Only 113 of the 132 LDL variants were available in the T2D results. We used a Bonferroni correction for 132 variants to determine the significance of the results (α = 4.0 × 10 −4 ).
Association of PCSK9 p.Arg46Leu with type 2 diabetes. For evaluating the association of PCSK9 p.Arg46Leu with risk of T2D, we considered a total of 42,011 T2D cases and 180,834 controls from 30 studies from populations of European ancestry (Supplementary Table 18 ). The variant was directly genotyped in all studies by using the Metabochip or the Exome array. Sample and variant quality control was performed within each study, as described previously [47] [48] [49] [50] . Within each study, the variant was tested for association with T2D under an additive model after adjustment for study-specific covariates, including principal components to adjust for population structure. Association summary statistics for the variant for each study was corrected for residual population structure by using the genomic-control inflation factor, as described previously [47] [48] [49] . We then combined association summary statistics for the variant across studies via fixed-effects inverse-variance-weighted meta-analysis. from the third generation underwent multidetector computed tomography, through which we evaluated liver attenuation, as previously described 51 . We tested the association of TG variants with CT liver fat after inverse normal transformation. Covariates in the regression models included age, age squared, and sex. A similar analysis was conducted in 3,293 participants of European ancestry from the BioImage study 52 . Association results for liver attenuation from the Framingham and BioImage studies were combined through fixedeffects inverse-variance-weighted meta-analysis. (iii) T2D: data were from the ExTexT2D Consortium 39 . (iv) CAD: results were from the published Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia study 40 and analysis of the UK Biobank, combined through meta-analysis.
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